Source comparison
Injury Recovery Peptides 2026 Update: Compound Comparison
BPC-157 VEGF upregulation, NO pathway modulation Gastric mucosa, vascular-rich soft tissue 28 days at 2–8°C 52% faster gastric ulcer healing at 14 days (Zagreb 2025) Best for mucosal and high-perfusion injuries; ineffective in avascular tissue TB-500 Actin pol
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, NO pathway modulation
- Gastric mucosa, vascular-rich soft tissue
- 28 days at 2–8°C
- 52% faster gastric ulcer healing at 14 days (Zagreb 2025)
- Best for mucosal and high-perfusion injuries; ineffective in avascular tissue
- TB-500
- Actin polymerization, angiogenesis promotion
- Tendons, muscle, endothelial tissue
- 21 days at 2–8°C (oxidation-sensitive)
- 34% improved tendon healing at 8 weeks (Tissue Eng 2025)
- Highly effective in soft tissue; minimal cartilage/bone impact
- Thymalin
- Thymic peptide complex, immune modulation
- Systemic immune response, wound sites
- 28 days at 2–8°C with cysteine protection
- 40% reduction in post-surgical infection markers (Moscow Institute 2024)
- Immune-focused rather than tissue-specific; adjunct to other peptides
- MK-677
- Growth hormone secretagogue
- Bone, muscle, systemic anabolism
- Oral bioavailability. No reconstitution required
- 18% increase in lean mass at 12 weeks (Phase II, 2023)
- Not injury-specific but supports systemic recovery environment
- The 2026 update to injury recovery peptides research didn't introduce new compounds. It clarified which existing peptides work in which contexts and why prior studies showed inconsistent results. TB-500 remains the most cited peptide for soft tissue injuries, but only in tissues with high endothelial density. BPC-157 continues to dominate gastric and mucosal research but fails in avascular environments. The breakthrough was protocol standardization, not peptide discovery.